Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Newcelx Ltd (NCEL)

Newcelx Ltd (NCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes PR Newswire - Mon Mar 9, 6:00AM CDT

Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation

NCEL : 2.43 (+0.41%)
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy PR Newswire - Thu Feb 12, 6:00AM CST

Publication strengthens scientific positioning as Company progresses strategic discussions related to CVR-linked asset

NCEL : 2.43 (+0.41%)
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences PR Newswire - Thu Jan 29, 6:00AM CST

Reinforces strategic focus on Type 1 Diabetes cell therapy and highlights expansion of Scientific Advisory Board and leadership team

NCEL : 2.43 (+0.41%)
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression PR Newswire - Mon Jan 12, 6:00AM CST

ZURICH , Jan. 12, 2026 /PRNewswire/ --  NewcelX Ltd . (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported...

NCEL : 2.43 (+0.41%)
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board PR Newswire - Mon Jan 5, 6:00AM CST

ZURICH and NESS ZIONA, Israel , Jan. 5, 2026 /PRNewswire/ --  NewcelX Ltd . (NASDAQ: NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative...

NCEL : 2.43 (+0.41%)
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China PR Newswire - Thu Dec 11, 2025

Publication in key market advances NewcelX's global IP strategy across Asia and supports the Company's expanding position in neurology and metabolic diseases

NCEL : 2.43 (+0.41%)
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute PR Newswire - Mon Nov 17, 2025

ZURICH and NESS ZIONA, Israel , Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd . (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule...

NCEL : 2.43 (+0.41%)
NLSP : 7.6200 (+2.97%)
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board PR Newswire - Thu Nov 6, 2025

ZURICH , Nov. 6, 2025 /PRNewswire/ --  NewcelX Ltd. (NASDAQ: NCEL) ("NewcelX" or the "Company"), a biotechnology company advancing transformative therapies for neurodegenerative and metabolic...

NCEL : 2.43 (+0.41%)
NewcelX CEO Issues Letter to Shareholders PR Newswire - Tue Nov 4, 2025

ZURICH , Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd . (Nasdaq: NCEL), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies for neurodegenerative and...

NCEL : 2.43 (+0.41%)
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd. PR Newswire - Mon Nov 3, 2025

ZURICH , Nov. 3, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a Swiss clinical-stage biopharmaceutical company developing cell-based and small-molecule therapies...

NCEL : 2.43 (+0.41%)

Barchart Exclusives

Williams-Sonoma Just Raised Its Dividend 15%. Should You Buy the Blue-Chip Stock Here? Barchart - 8 minutes ago
Williams-Sonoma is rewarding shareholders with a 15% dividend hike and steady execution. Does this consistency leave upside on the table? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.